Zobrazeno 1 - 5
of 5
pro vyhledávání: '"544"'
Autor:
Toshiki Uchida, Michinori Ogura, Kensei Tobinai, Takashi Watanabe, Kiyohiko Hatake, Masahiro Yokoyama, Junko Ohata, Masanobu Kasai, Masanao Akiyama, Yasuhito Terui, Chiho Ono, Yukio Kobayashi
Publikováno v:
Blood. 112:1565-1565
Introduction: Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapeutic agent composed of a monoclonal antibody which targets the CD22 antigen, conjugated to calicheamicin, a potent cytotoxic antitumor antibiotic. Since CD22 is express
Publikováno v:
Blood. 128:4795-4795
Introduction MMF is an immunosuppressive drug frequently used for graft-versus-host disease (GVHD) prophylaxis and management. MMF-induced colitis is a known complication, however, details regarding its clinical manifestations, treatment options, and
Autor:
Emma Gee, Lara N. Roberts, Raj K. Patel, Cara Doyle, Julia Czuprynska, Kathryn Jane Lang, Ruochen Li, Roopen Arya
Publikováno v:
Blood. 126:3550-3550
There are clearly demonstrated links between unprovoked venous thromboembolism (VTE) and underlying malignancy. Previous studies have shown an incidence between 3 and 13% of subsequent cancer diagnoses in patients with unprovoked VTE. National guidan
Autor:
Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O'Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, Yanfeng Wang, for the IRIS Study Group [, BACCARANI, MICHELE
Publikováno v:
Blood. 111(8)
Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic phase. We here describe the correlation of imatinib trough plasma concentrations (Cmins) with clinical responses, event-free survival (EFS), and adverse events (AE
Autor:
Ronald Sobecks, Steven Andresen, Brian T. Hill, Brian J. Bolwell, Lisa Rybicki, Aleksandr Lazaryan, John Sweetenham, Brad Pohlman, Shawnda Tench, Matt Kalaycio, Edward A. Copelan, Robert M. Dean, Hien K. Duong
Publikováno v:
Blood. 118:4122-4122
Abstract 4122 Bone marrow (BM) involvement at the time of initial diagnosis occurs in 4%-14% of patients (pts) with Hodgkin (HL) and 18%-39% with non-Hodgkin (NHL) lymphomas. Both clinical and prognostic implications of BM involvement are largely rel